


OCUTEIN®

LUTEIN 15 mg

GINKGO



NEW!
FOCUSED
on my vision



- **one ocular nutrition** 4 categories of nutrients (Ginkgo biloba, Omega 3, carotenoids and antioxidants) which are important for the nutrition of the eye and maintaining natural protective system
- **long-lasting nourishment of the retina and supporting peripheral circulation eyes** (Ginkgo biloba)
- **limitation of the development of inflammatory and degenerative disorders of the eye** (lutein, zeaxanthin)

available in two packaging market

Ocutein® GINKGO Lutein 15 mg Da Vinci Academia 30 capsules

Ocutein® GINKGO Lutein 15 mg Da Vinci Academia 60+30 capsules

OCUTEIN®

LUTEIN 15 mg

GINKGO



A unique eye nutrition with 4 categories of nutrients

1. **Ginkgo biloba** - improves the function of the optic nerve and retina
2. **Omega-3 PUFA (DHA a EPA)** - sclerotic effectiveness of eye blood vessels
3. **Carotenoids (lutein, zeaxanthin, vitamin A)** - protects the nerve cells in the macula
4. **Antioxidants (vitamin C, zinc, selenium)** - essential for proper visual function

Why use Ocutein® GINKGO 15 mg Lutein?


- It contains a higher and more effective dose supplementation of lutein / zeaxanthin for **faster onset and longer protective activity**.
- Ginkgo biloba extract **synergistically consolidates the effect of lutein, zeaxanthin and omega-3 PUFA** and relatively clearly improves blood flow to the optic nerve and improves vision.
- **Omega-3 PUFAs improve the bioavailability of lutein / zeaxanthin** (must prevail over omega-3 omega-6 PUFA, in the case of superiority of omega-6 PUFAs a positive modulatory effect on the cognitive function and sight cannot be expected).

Table of nutrition values

Ingredients:	In 1 Capsule	% RI- References Intake
Lutein	14 mg	not specified
Zeaxanthin	1 mg	not specified
Ginkgo extract 24/6 (Ginkgo biloba)	45 mg	not specified
Vitamin A (retinyl palmitate)	628 µg	79%
DHA (docosahexaenoic acid)	250 mg	not specified
EPA (eicosapentaenoic acid)	36 mg	not specified
Zinc (zinc oxide)	14 mg	140%
Selenium (sodium selenite)Selenium (sodium selenite)	26 µg	47%
Vitamine C (L-sodium ascorbate)	100 mg	80%

Fish oil (70% DHA, 10% EPA), capsule:gelatin; sodium ascorbate, capsule: glycerol; emulsifier: soy lecithin; lutein oil suspension 20%, polishing agent: beeswax, Ginkgo extract 24/6, filler: soybean oil, capsule: purified water, zinc oxide, devitalised biomass beer yeast with selenium, oil zeaxanthin oil suspension 10%, dyes: caramel coloring; retinol palmitate.

Dosage: 1 capsule a day



This material is intended for health professionals and not the general public.
Swiss Pharmaceutical Investment has developed and is responsible for this document.

Selected specialist references:

- Thürmann, P.A.**, Schalch, W., Aebischer, J.C., Tenter, U., Cohn, W. Plasma kinetics of lutein, zeaxanthin, and 3-dehydro-lutein after multiple oral doses of a lutein supplement. *Am.J.Clin.Nutr.* 82 (1), 2005:88-97.
- Sandberg, M.A.**, Johnson, E.J., Berson, E.L. The relationship of macular pigment optical density to serum lutein in retinitis pigmentosa. *Invest Ophthalmol Vis Sci.* 51 (2), 2010:1086-1091.
- Bahrami, H.**, Melia, M., Dagnelie, G. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]. *BMC Ophthalmol.* 6, 2006:23.
- Bartlett, H.**, Howells, O., Eperjesi, F. The role of macular pigment assessment in clinical practice: a review. *Clin Exp Optom.* 93 (5), 2010:300-308.
- Runcán, J.L.**, Aleman, T.S., Gardner, L.M., De Castro, E., Marks, D.A., Emmons, J.M., Bieber, M.L., Steinberg, J.D., Bennett, J., Stone, E.M., MacDonald, I.M., Cideciyan, A.V., Maguire, M.G., Jacobson, S.G. Macular pigment and lutein supplementation in choroideremia. *Exp Eye Res.* 74 (3), 2002:371-381.
- Aleman, T.S.**, Duncan, J.L., Bieber, M.L., de Castro, E., Marks, D.A., Gardner, L.M., Steinberg, J.D., Cideciyan, A.V., Maguire, M.G., Jacobson, S.G. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. *Invest Ophthalmol Vis Sci.* 42 (8), 2001:1873-1881.
- Bone, R.A.**, Landrum, J.T. Dose-dependent response of serum lutein and macular pigment optical density to supplementation with lutein esters. *Arch Biochem Biophys.* 504 (1), 2010:50-55.
- AREDS2 Research Group.** The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). *Ophthalmology* 119 (11), 2012:2282-2289.
- Age-Related Eye Disease Study 2 Research Group, collaborators (23).** Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA.* 309 (19), 2013:2005-2015.
- Age-Related Eye Disease Study 2 (AREDS2) Research Group, collaborators (23).** Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. *JAMA Ophthalmol.* 131 (7), 2013:843-850.
- Ramkumar, H.L.**, Tuo, J., Shen de, F., Zhang, J., Cao, X., Chew, E.Y., Chan, C.C. Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background. *J Nutr.* 143 (7), 2013:1129-1135.
- Raz, R.**, Carasso, R.L., Yehuda, S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. *J Child Adolesc Psychopharmacol.* 19 (2), 2009:167-177.
- Garcia-Layana, A.**, Recalde, S., Alaman, A.S., Robredo, P.F. Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial. *Nutrients.* 5 (2), 2013:543-551.
- Gleize, B.**, Tourniaire, F., Depeyaz, L., Bott, R., Nowicki, M., Albino, L., Lairon, D., Kesse-Guyot, E., Galan, P., Hercberg, S., Borel, P. Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability. *Br J Nutr.* 110 (1), 2013:1-10.
- Shanmugasundaram, R.**, Selvaraj, R.K. Dietary lutein and fish oil interact to alter atherosclerotic lesions in a Japanese quail model of atherosclerosis. *J Anim Physiol Anim Nutr (Berl).* 95 (6), 2011:762-770.
- Selvaraj, R.K.**, Shanmugasundaram, R., Klasing, K.C. Effects of dietary lutein and PUFA on PPAR and RXR isomer expression in chickens during an inflammatory response. *Comp Biochem Physiol A Mol Integr Physiol.* 157 (3), 2010:198-203.
- Zampatti, S.**, Ricci, F., Cusumano, A., Marsella, L.T., Novelli, G., Gardina, E. Review of nutrient actions on age-related macular degeneration. *Nutr Res.* 34 (2), 2014:95-105.
- Fies, P.**, Diemel, A. Ginkgo extract in impaired vision – treatment with special extract Egb 761 of impaired vision due to dry senile macular degeneration. *Wien Med Wochenschr.* 152 (15-16), 2002:423-426.
- Page, J.W.**, Findley, J., Crognale, M.A. Electrophysiological analysis of the effects of ginkgo biloba on visual processing in older healthy adults. *J Gerontol A Biol Sci Med Sci.* 60 (10), 2005:1246-1251.
- Park, J.W.**, Kwon, H.J., Chung, W.S., Kim, C.Y., Seong, G.J. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. *Korean J Ophthalmol.* 25 (5), 2011:323-328.
- Bernardczyk-Meller, J.**, Siwiec-Proscinska, J., Stankiewicz, W., Fichna, P., Pecold, K., Korman, E. Influence of Egb 761 on the function of the retina in children and adolescent with long lasting diabetes mellitus-preliminary report. *Klin Oczna.* 106 (4-5), 2004:569-571.
- Guo, X.**, Kong, X., Huang, R., Jin, L., Ding, X., He, M., Liu, X., Congdon, N.G. Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial. *Invest Ophthalmol Vis Sci.* 55 (1), 2014:110-116.